Astonea Labs was incorporated on April 11, 2017. The company manufactures and markets pharmaceutical and cosmetic products, offers contract manufacturing, and exports to Iraq and Yemen. It owns brands like Glow Up and Regero and is expanding globally after a recent USFDA audit for OTC products
| Bidding Dates |
|---|
| 27 May 2025 - 29 May 2025 |
| Subscription |
|---|
| 2.44x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹1,28,000 | 1 | 1 | 1000 | 2.8 M | ₹128 - ₹135 | 72.3 % | ₹357.1 M - ₹376.6 M | RHP DOC |
Astonea Labs IPO SUBSCRIPTION STATUS
29 May '25Astonea Labs IPO overall subscription rate was 2.44 times the total available shares
Astonea Labs IPO retail subscription rate was 2.24 times in the retail segment
Astonea Labs IPO non-institutional investor subscription rate was 7.92 times in the non-institutional investor category
Astonea Labs IPO Qualified Institutional Bidder subscription rate was 0.93 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
29 May 2025 (Day 3) | 2.24x | 7.92x | 0.93x |
28 May 2025 (Day 2) | 0.9x | 3.51x | 0.15x |
27 May 2025 (Day 1) | 0.47x | 0.87x | - |
Astonea Labs FINANCIALS
| Period | Net Profit (Rs in crore) | Revenue from Operations (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| 9MFY25 | 4.1 | 69.6 | 2.8 | 2.8 | 15.9% |
| FY24 | 3.8 | 80.2 | 4.0 | 4.0 | 14.6% |
| FY23 | 0.7 | 67.1 | -1.1 | -1.1 | 10.5% |
| FY22 | 0.2 | 30.1 | -4.9 | -4.9 | 18.8% |
Astonea Labs IPO SUBSCRIPTION STATUS DETAILS
Astonea Labs had 2.8 M shares on offer
Astonea Labs IPO offer price was in the range ₹128 - ₹135
Astonea Labs IPO minimum Investment was ₹128000
Astonea Labs IPO issue size was ₹ 357.1 M - ₹ 376.6 M
Astonea Labs had a minimum lot size of 1000 Shares per application
Astonea Labs NUMBER OF SHARES ON OFFER
Astonea Labs IPO IMPORTANT DATES
| Issue Open Date | 27 May 2025 |
| Issue close Date | 29 May 2025 |
| Allotment Date | 30 May 2025 |
| Refund Date | 02 Jun 2025 |
| Demat Account Credit Date | 02 Jun 2025 |
| Listing Date | 03 Jun 2025 |
| Listing on Exchange(s) | BSE |
| Astonea Labs Allotment Status | Exchange/ Registrar |
Astonea Labs IPO subscription opened on 27 May 2025, and closed on 29 May 2025
IPO allotment for Astonea Labs was finalized on Friday, 30 May 2025
IPO listing for Astonea Labs was on BSE on Tuesday, 03 Jun 2025
Astonea Labs IPO LISTING GAINS
| Issue Price (adjusted) | 135.0 |
| Listing Open Price | 137.4 |
| Listing Close Price | 135.7 |
| Listing Gain% | 1.8% |
| Current Gain% | 100.0% |
Astonea Labs Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astonea Labs Ltd. | 270 | 283.8 | 62.8 | -4 | 1.9 | 7.9 | 3.1 | 148.1 | 51.6 | 4.5 | -15.6 | 4.3 | -15.6 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Astonea Labs INFORMATION ON IPO ISSUE
About Astonea Labs
Astonea Labs was incorporated on April 11, 2017. The company manufactures and markets pharmaceutical and cosmetic products, offers contract manufacturing, and exports to Iraq and Yemen. It owns brands like Glow Up and Regero and is expanding globally after a recent USFDA audit for OTC products
Object of the Issue
- Funding of expenses proposed to be incurred towards product registration in Bolivia, South America
- Purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols
- Advertising, marketing and brand building
- Investment in procuring hardware and software
- Funding of working capital requirements
- General corporate purposes
Astonea Labs - PROMOTERS
| Name |
|---|
| Ashish Gulati |
Astonea Labs Book Running Lead Manager
Oneview Corporate Advisors Private Limited
mbd@oneviewadvisors.com
Astonea Labs Registrar to the issue
KFin Technologies Limited
astonea.ipo@kfintech.com
Astonea Labs Strengths
Scalable business model
The company follows a customer-centric, order-driven approach focusing on optimal resource utilisation and consistent product quality. This enables it to efficiently scale operations by expanding into new domestic and international markets
Diverse product portfolio
The company offers a broad range of pharmaceutical and cosmetic products covering therapeutic areas such as antibiotics, antihistamines, diabetes, cardiovascular and gynaecological care, along with multivitamins, skin, and hair care solutions
Quality-focused service
The company emphasises timely and high-quality service through strict internal systems that minimise errors and ensure prompt delivery. This commitment has led to strong customer goodwill, high retention rates, repeat orders, and a growing client base
Astonea Labs Risks
FDA fee non-compliance
The company has not yet satisfied its annual OTC Monograph User Fee obligation under the US FDA's program. This non-compliance renders all its OTC drug products as misbranded and bars them from interstate commerce in the US, potentially damaging its market access and reputation
Supply chain uncertainty
The company does not maintain long-term contracts with suppliers, exposing it to raw material price volatility and potential supply disruptions. Pricing is negotiated per order, increasing the risk of delays or production halts in the event of shortages or supplier exit
Regulatory compliance exposure
Operating in the tightly regulated pharmaceutical and cosmetics industries, the company is subject to stringent quality and manufacturing standards. Non-compliance with regulatory requirements across jurisdictions, including those set by the US FDA and other authorities could lead to fines, product recalls, or reputational damage
IPO FAQs
The promoter of the company is Ashish Gulati.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 128.0 - 135.0.
The IPO application opens on May 27, 2025 and closes on May 29, 2025.
The minimum lot size for the IPO is 1000. The maximum lot size for the IPO is 1000.
For all category investors, the minimum application amount for this IPO is Rs. 128,000.0, the maximum value for this IPO is Rs 135,000.0.
This IPO will be allotted on May 30, 2025.
The refund will be credited to your account on Jun 02, 2025.
The allotted shares will be credited to your demat on Jun 02, 2025.
Astonea Labs Ltd.’s shares listed on the stock exchanges on Jun 03, 2025.